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1. Introduction
In 2011 two extensive studies were published about prevalence and associated 
disability, including the associated disease burden and financial costs, of brain 
diseases in Europe [1–3]. A shocking finding was that in a European population 
of more than 400 million people, approximately one-third suffered from a psy-
chiatric or neurological disorder. In the psychiatric disorders, anxiety disorders 
had the highest 12-month prevalence (14%) and depression (7%), approximately 
61.5 million people. The disability burden of psychiatric diseases including major 
depression is tremendous being defined in disability-adjusted life years (DALYs). 
In 2010, more than 26% of all cumulated disease burden in Europe was due to brain 
disorders; depression belongs to the top diseases with the highest DALYs. Major 
depression is a severe brain disorder associated with long-term disability and low 
quality of life. Suicide and suicidal attempts are highly associated with depression 
and have an enormous impact on relatives and society.
2. Antidepressants
Since the 1950s and 1960s of the last century, discovery and development of 
antidepressants have gradually emerged. Early antidepressants like imipramine and 
the irreversible monoamine oxidase inhibitors (MAOI) were discovered by seren-
dipity. These “accidental” discoveries have led to intensive research and have led 
to a series of new antidepressants, like the tricyclic class (TCA, e.g., imipramine, 
nortriptyline, amitriptyline, and clomipramine) and a series of (both reversible 
and irreversible) MAOIs. These antidepressants, although still clinically available, 
are not anymore first-line medicines, mainly because of their sometimes severe 
side effects. The research in the 1960s and 1970s led to the insight that TCAs block 
monoamine transporters (reuptake carriers) for serotonin and noradrenaline to 
varying extent. Some TCAs are preferential serotonin transporter (SERT) blockers 
(clomipramine, amitriptyline), while others are preferential noradrenaline trans-
porter (NET) blockers (desipramine, maprotiline) or mixed SERT/NET blockers 
(doxepin, imipramine). TCAs also block several neurotransmitter receptors, 
particularly muscarinic cholinergic, H1 histaminergic, and α1-adrenoceptors, which 
is mainly responsible for their (unwanted) side effects, including sedation, dry 
mouth, and constipation.
Based on the early, but overly simplistic hypothesis that low serotonin and/or 
noradrenalin levels/activity in the brain are associated (or even causative in) with 
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depression, the development of selective serotonin reuptake inhibitors (SSRIs; 
fluoxetine, fluvoxamine, sertraline, paroxetine, citalopram, escitalopram) and 
selective noradrenaline reuptake inhibitors (NRIs; reboxetine, atomoxetine) and 
mixed 5-HT/NA reuptake blockers (SNRIs: venlafaxine, duloxetine) was enabled. 
Several other antidepressants have been developed (e.g., bupropion, mirtazapine, 
agomelatine, trazodone, nefazodone), with variable mechanisms of action. In 
general, SSRIs are the drugs of choice and first-line in the treatment of major 
depression [4]. The first SSRIs (zimeldine, fluvoxamine) were introduced in the 
early 1980s [5], and in the ensuing decade, several followed (fluoxetine, paroxetine, 
sertraline). Up to this moment, SSRIs still are first-line medication in MDD, but 
some breakthrough antidepressants are emerging (esketamine), whereas extensive 
and intensive research and development are ongoing [6].
3. Antidepressants: how good are they?
SSRIs like all antidepressants come with associated problems, viz., (1) side 
effects, (2) limited efficacy, and (3) slow onset of action.
3.1 Side effects
Major depressive disorder (MDD) typically comes in recurrent depressive 
episodes rather than a single episode. Antidepressant treatment requires to focus on 
both acute and maintenance aspects of MDD. The primary goal of the acute treat-
ment phase (8–12 weeks) is to achieve symptomatic remission. In the acute phase, 
emerging side effects of the first-line treatment (often an SSRI) and the toler-
ance development of the patient strongly co-determine a positive antidepressant 
response to SSRIs or SNRIs. Main side effects (occurring in approximately 10–30% 
of patients) are nausea, dry mouth, sweating, sexual dysfunction, somnolence, 
nervousness, anxiety, dizziness, and insomnia [7]. If SSRI/SNRI treatment is not 
effective, MAO inhibitors or TCAs (as third-line treatments) may be used, although 
they come with additional and often more severe side effects. Second-line treatment 
includes novel antidepressants like vilazodone or vortioxetine or second-generation 
antidepressants like agomelatine, bupropion, or mirtazapine. All have their own 
side effect profile and are comparably effective antidepressant compared to SSRIs 
and others [8]. Lifetime major depression has high psychiatric comorbidity with 
anxiety disorders, substance use disorders, and impulse control disorders. Many 
depressed patients have medical (physical) comorbidities requiring pharmaco-
therapy, and this brings the risk of drug-drug interactions, often associated with 
cytochrome (CYP) P450 or P-glycoprotein-mediated effects. This may exacerbate 
side effects of drugs or interfere with the pharmacological action.
The most disturbing side effects of SSRIs and some TCAs (e.g., clomipramine) 
are those on sexual functioning like libido, orgasm, and arousal problems. In con-
trast to some other side effects that are prominent in the first phase of treatment, 
but often diminish upon drug continuation (like nausea and dizziness), sexual 
side effects do not disappear and are often causing drug discontinuation. MDD 
itself is already associated with 50–70% enhanced risk of sexual dysfunction (SD), 
and prescribing antidepressants with inherent effects on sexual behavior strongly 
enhances the risk for noncompliance or discontinued drug-taking [9]. Such a 
scenario can be avoided by prescribing (e.g., as second-line choice) antidepressants 
without (or less) sexual side effects (e.g., agomelatine, bupropion, vilazodone, or 
vortioxetine). Because depression occurs during all life phases, it is also common 
during pregnancy with an estimation of 20% of women that experience depressive 
3Introductory Chapter: Antidepressants - Preclinical, Clinical and Translational Aspects
DOI: http://dx.doi.org/10.5772/intechopen.86476
symptoms during that time [10], whereas around 4–8% of pregnant women suffer 
from MDD. Depression of the mother impacts the fetus, e.g., by the enhanced cor-
tisol levels in the mother which also pass the placenta. There is strong evidence that 
increased stress levels of the mother may lead to neurological and behavioral changes 
in the child which persists at least into adolescence (e.g., [11]). In the contribution 
of Staal and Olivier (Chapter 2), a review is given of the consequences of depression 
during pregnancy. Although the consequences for a child, adolescent, or adult that 
was in utero subject to a mother experiencing MDD are not yet completely clear, the 
first results point to a negative influence [12]. However, nowadays a considerable 
number (2–3%) of pregnant women with MDD are treated with antidepressants, 
mostly with SSRIs. SSRIs cross the placenta and reach the fetus, including the central 
nervous system. Because serotonin plays a key role in embryonic development as a 
neurotrophic factor, disturbances in its level might lead to (permanent) changes in 
the offspring [13–15]. Chapter 2 summarizes the state of the art of the interaction 
between untreated or SSRI-treated mothers with severe depression. It is not yet clear 
whether SSRI treatment or not is preferable for depression in pregnant women.
3.2 Limited efficacy
Antidepressants have limited efficacy in relieving depressive symptoms in 
MDD patients. It is estimated that approximately 50% of depressed patients are 
adequately treated by the available interventions, including pharmacotherapy [16]. 
Most patients receiving pharmacotherapy fail to achieve and sustain remission, 
eventually not leading to functional recovery. The majority of patients starting an 
antidepressant require several subsequent and different antidepressants or adjunc-
tive therapy (either pharmacological or cognitive behavioral therapy). There is 
evidence that if a chosen treatment strategy (a certain antidepressant, often an 
SSRI) results in symptomatic improvement within the first weeks, full remission is 
likely, but the reverse is also true: lack of early improvement predicts a high chance 
on non-remittance [17]. After failure of a number of (adequately dosed) antide-
pressants of different classes (SSRI, TCA, MAOI), and augmentation with various 
drugs (e.g., antipsychotics) and other strategies (e.g., cognitive behavioral ther-
apy), patients are considered treatment-resistant. Treatment-resistant depression 
(TRD) is defined as the failure to respond to one or more standard antidepressant 
treatment trials of adequate dosing and duration [18, 19]. TRD is a big challenge to 
treat. Although depression is diagnosed as a single entity, MDD [20] is an extremely 
heterogeneous disease [21] with regard to symptoms, etiologies, and pathophysiolo-
gies, with some moderately heritable background [22] and a high susceptibility to 
adverse life events [23]. TRD reflects a complex, heterogeneous state, probably with 
multiple causal underlying mechanisms. It is not clear how and where TRD patients 
differ from non-TRD patients, although early life stress seems to facilitate treat-
ment resistance [24]. Research is clearly needed to establish the pathophysiology of 
TRD, the complex mechanisms involved, and the heterogeneity of the TRD patient. 
Unfortunately, depression is presently not a high priority for pharmaceutical 
companies, due to recent failures in antidepressant discovery and lack of under-
standing of the mechanisms involved and the consequent lack of available targets. 
Akil et al. [21] argue a need of a fundamental approach in the search for new and 
effective treatments for TRD. They propose to identify dysfunctional brain circuitry 
in animal models of depression, looking at changes in associated gene expression. 
Combination of animal research with human genetic and imaging studies must 
generate circuits and molecules that are both altered in the animal models of TRD 
and also in selected patient populations. Such translational and highly integrated 
research may lead to new targets for specific anti-TRD medication.
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In Chapter 3 Marek and colleagues describe the research on orexin 2 receptor 
antagonists as putative new antidepressants. Orexin, a hypothalamic neuropeptide, 
is known for its involvement in sleep-wake cycling of all mammals, including 
man. Orexin 2 receptor antagonists produce antidepressant activity in animal tests 
sensitive for antidepressant activity, including the DRL-72 sec schedule of rein-
forcement, an advanced screen for antidepressants [25]. Both positive and negative 
preliminary human data are present on orexin 2 receptor antagonists in depression, 
but further studies are needed to answer whether this approach might lead to new 
antidepressants or may be also effective in treatment-resistant depression.
3.3 Slow onset of action
The current most widely prescribed antidepressants, SSRIs and SNRIs, but also 
TCAs and MAOIs and other antidepressants, have no acute onset of action but work 
(gradually) over a period of weeks to months. It is still largely unknown what under-
lying CNS mechanisms are involved in the slow onset of action of antidepressants. 
In the case of serotonergic antidepressants (SSRIs, SNRIs), a complex interaction 
between various 5-HT auto- and heteroreceptors as modulators of the SSRI-induced 
chronic increase in CNS serotonin plays a role [26]. Acute administration of SSRIs 
Inhibits somatodendritic 5-HT1A autoreceptors leading to inhibition of firing activity 
of serotonergic neurons and consequently dampened release of 5-HT in the fore-
brain, which, in some not yet understood way, contributes to the slow onset of action 
of SSRIs [27]. Desensitization of 5-HT1A autoreceptors after long-term administra-
tion might overcome the decrease in 5-HT release and subsequently would lead to 
high serotonin release [27]. Combining an SSRI and 5-HT1A-receptor antagonist 
might create a fast onset of action mechanism for antidepressant activity. The lack of 
availability of clinically approved selective 5-HT1A receptor antagonists led to studies 
using the mixed β-adrenoceptor/5-HT1A receptor antagonist pindolol together with 
various SSRIs in MDD patients [28]. In a placebo-controlled study, pindolol increased 
the antidepressant efficacy of fluoxetine, although no significant improvement in 
onset of action of the combination was found [29]. Pindolol is probably not the best 
tool to perform this kind of “onset of action” studies (pindolol is a relatively weak 
and not a full 5-HT1A receptor antagonist, and its beta-blocking activities induce side 
effects), but a study with a selective 5-HT1A-receptor antagonist did not find any 
difference either. It was postulated [30, 31] that two new multi-target antidepres-
sants, vilazodone (SSRI+ partial 5-HT1A receptor agonist) and vortioxetine (SSRI+5-
HT1A,1B,1D,7 receptor agonist and 5-HT3 receptor antagonist), might have an advantage 
over existing drugs in terms of efficacy and onset of antidepressant action, although 
clinical data thus far have not shown evidence for improving the onset of action [32, 
33]. It is evident that antidepressants that primarily act via monoaminergic neuro-
transmission all share the slow onset of action principle, and new molecules stem-
ming from this “classical” approach will not deliver fast onset of action compounds.
The finding that one single dose of intravenous ketamine produced rapid and sus-
tained antidepressant effects in depressed patients led to a new and exciting opening 
in this field [34]. Ketamine, an NMDA receptor antagonist and dissociative anesthetic, 
produces at low doses mild dissociative and psychotomimetic effects but also exerted 
rather unexpected antidepressant effects. One single dose of ketamine (0.5 mg/kg, 
intravenously by slow infusion) induced a rapid antidepressant effect (within hours) 
that lasted for 7 days [35]. Later studies have confirmed the fast antidepressant onset, 
even in TRD patients [6]. However, notwithstanding the apparent breakthrough 
in fast treatment of depression, the side effects of ketamine are still troublesome 
for general use. Recently (March 2019) a nasal preparation of the (S)-enantiomer 
(esketamine) received FDA approval after successful phase 3 trials. Moreover, 
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new approaches for fast-onset and effective antidepressants via modulation of the 
glutamatergic-NMDA system are now subject of intense research efforts [6, 36]. One 
may expect a new range of novel antidepressants with as main attribute a fast onset 
of action. Whether these new molecules have a higher efficacy (>50% of responding 
patients) or accordingly lead to less treatment resistance has to be awaited. Moreover, 
the side effect profile is likely quite different from the classical “monoaminergic” 
antidepressants. Only large number of well-treated patients will unravel the impact of 
these side effects. If only the onset of action is improved, the acceptance of such a new 
antidepressant will strongly depend on its side effect and safety profile.
One of the big items in the research and discovery of new and innovative 
antidepressants is the availability of animal models that are able to measure “onset 
of action,” “efficacy,” and “side effects” [37]. Onset of antidepressant action in an 
animal model is quite difficult to assess. Most animal depression tests are acute, in 
that they respond immediately to a dose of a certain antidepressant, e.g., forced 
swim test, tail suspension test, or DRL-72 sec paradigm. Animal depression models 
that do not respond acutely but only after chronic treatment of the classic antide-
pressants are rather scarce, although indispensable in the onset of action discovery. 
One of such models is the olfactory bulbectomized (OBX) rat [37, 38]. OBX leads to 
stable and lasting changes in behavior after removing the olfactory bulbs [39]. OBX 
leads within days after ablation to permanent changes in activity, basal body tem-
perature, heart rate and heart rate variability, and stress responsivity [39]. Increased 
locomotor activity in an open field is an often used simple parameter to measure the 
effects of antidepressants [38]. In an extensive review on available animal models, 
olfactory bulbectomy in rodents is considered superior to other animal models to 
detect onset of action of antidepressants [37], with a high sensitivity, specificity, 
and reliability and moderate ease to use the model. The model generated also the 
possibility to study effects of antidepressant treatment after cessation of treatment 
[40]. Chronic (14-day) treatment of imipramine (20 mg/kg) or escitalopram (5 
and 10 mg/kg) in OBX and sham-operated rats led to reduction of the hyperactiv-
ity in an open field by imipramine and escitalopram of the OBX rats, without 
effects in the control rats. This reduction in hyperactivity of OBX rats induced by 
chronic administration of antidepressants remained after cessation of treatment 
and lasted for 10 weeks after imipramine and 6 weeks after escitalopram cessation 
[40]. We concluded that the OBX-induced changes in the brain state (neuroplas-
ticity) are probably attenuated by chronic antidepressant administration and that 
these changes are only slowly returning to the previous OBX state. Pramipexole, a 
dopamine D3/D2 receptor agonist, used to treat Parkinson patients with additional 
antidepressant activity [41], indeed exerted antidepressant activity in the OBX 
model [42]. Pramipexole is also a psychostimulant and induces at higher doses 
enhanced locomotion itself, thereby interfering with the already enhanced activity 
of OBX rats. Remarkably, 1 week after cessation of treatment, pramipexole-treated 
OBX animals still were not hyperactive, similar to imipramine, thereby suggesting 
that antidepressant effects of drugs can be detected in the OBX model by using this 
post-cessation antidepressant-like effect [42]. Unpublished studies [43] found that 
3- and 7-day treatment with imipramine (10 mg/kg/day) normalized OBX-induced 
hyperactivity in the open field. One week after cessation of imipramine treatment, 
hyperactivity returned, suggesting that longer periods of treatment (14 days) are at 
least needed to lead to changes in brain neuroplasticity underlying the suppression 
of OBX-induced behavioral changes. In a complicated experimental design, ket-
amine (10 mg/kg, IP) was given to OBX and control rats 24 hours before testing in 
an open field but appeared ineffective [44]. The experimental design did not give a 
clear cue about the onset of action of antidepressant activity of ketamine, and more 
directed research into this avenue has to be initiated. Pandey et al. [45] found that 
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14-day but not 7-day treatment with ketamine (1 mg/kg/day) reduced hyperactivity 
induced by olfactory bulbectomy, although combination of escitalopram (10 mg/
kg/day) and ketamine (1 mg/kg/day) reduced hyperactivity at both 7 and 14 days. 
This may be an indication that ketamine in combination with an SSRI may speed up 
the onset of antidepressant action.
Recently the FDA has approved esketamine as a nasal spray for adjunctive 
therapy in treatment-resistant depression [46]. Esketamine is indicated for 
depressed patients that did not respond to at least two oral antidepressant mono-
therapies. It has to be given together with a newly initiated oral antidepressant 
under strict supervision of certified medical professionals, because of the potential 
serious adverse effects of esketamine. The launch of a successful potential anti-TRD 
medication might be a breakthrough in the treatment of depression.
4. Other applications for antidepressants
Apart from treatment of depression, antidepressants and particularly SSRIs and 
SNRIs are also widely used for treatment of various anxiety disorders, obsessive 
compulsive disorders, gambling disorders, posttraumatic stress disorder, and vari-
ous other psychiatric disorders, including alcohol use disorder.
In obsessive compulsive disorder, SSRIs are partially effective, but in general 
higher doses are needed, and onset of action (6–8 weeks) is slower than in depres-
sion. Because comorbidity of depression and anxiety is very high, it appeared that 
SSRIs could be used as a rational therapy for both disorders, although the disadvan-
tages of SSRIs in depression (side effects, onset of action, partial efficacy) are com-
parable in anxiety disorder treatment. In Chapter 4, Ballesta and coworkers review 
and discuss the role of antidepressants in alcohol use disorder (AUD). Because 
a strong relationship exists between major depression and AUD, the authors 
investigated the potential role of hippocampal plasticity and neurogenesis in both 
disorders. By integrating the knowledge of plasticity changes in the hippocampus 
and its role in both disorders, the authors try to implement shared mechanisms. It is 
clear that considerable research efforts, both preclinical and clinical, are needed to 
advance our possibilities to better treat both depression and alcohol use disorder.
5. Conclusion
The emergence of effective antidepressants in the 1960s and 1970s of the last 
century has led to an explosion of new and often unexpected new discoveries and 
clinical applications. The development of SSRIs after the serendipitous detection of 
the first tricyclic antidepressants has revolutionized the treatment of major depres-
sion but has also led to new treatments of various anxiety disorders, obsessive 
compulsive disorder, and various other psychiatric conditions.
Drug treatment always leads to side effects that can be quite cumbersome and 
often lead to drug discontinuation. Treatment resistance (TRD) is frequently occur-
ring in major depression, and a substantial part of depressed patients (about 30%) 
does not respond to any treatment. Recent developments (esketamine) promise 
new approaches in the treatment of TRD although side effects remain a big obstacle.
Research into new and better antidepressants remains urgent but depends pri-
marily on better understanding of the brain mechanisms involved in normal “mood” 
processing and understanding what is wrong in “depressed” brains. Animal models 
with high predictive and construct validity are urgently needed to help to discover 
these (dys)functional mechanisms and deliver new targets for better antidepressants.
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